Exploring the Ability of Electronic Nose Technology to Recognize Interstitial Lung Diseases (ILD) by Non-Invasive Breath Screening of Exhaled Volatile Compounds (VOC): A Pilot Study from the European IPF Registry (eurIPFreg) and Biobank.
Fiche publication
Date publication
octobre 2019
Journal
Journal of clinical medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BARRETO Guillermo
Tous les auteurs :
Krauss E, Haberer J, Maurer O, Barreto G, Drakopanagiotakis F, Degen M, Seeger W, Guenther A
Lien Pubmed
Résumé
There is an increasing interest in employing electronic nose technology in the diagnosis and monitoring of lung diseases. Interstitial lung diseases (ILD) are challenging in regard to setting an accurate diagnosis in a timely manner. Thus, there is a high unmet need in non-invasive diagnostic tests. This single-center explorative study aimed to evaluate the usefulness of electronic nose (Aeonose) in the diagnosis of ILDs.
Mots clés
European Registry for Idiopathic Pulmonary Fibrosis (eurIPFreg), electronic Nose (eNose, Aeonose®), idiopathic pulmonary fibrosis (IPF), interstitial lung diseases (ILD), volatile organic compounds (VOC)
Référence
J Clin Med. 2019 Oct 16;8(10):